

(FILE 'HOME' ENTERED AT 11:43:55 ON 22 OCT 2000)

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS, CANCERLIT, SCISEARCH, TOXLINE'  
ENTERED AT 11:44:30 ON 22 OCT 2000

L1	7360 S GEMCITABINE
L2	592347 S CHEMOTHERAP####
L3	2331 S L1 (P) L2
L4	7049 S HER-2 OR ERB-B2 OR CERB-B2
L5	23 S L1 (P) L4
L6	8 DUP REM L5 (15 DUPLICATES REMOVED)
L7	2124408 S CANCER
L8	4113 S L1 (P) L7
L9	440 S L1 (P) ((BREAST OR MAMMARY) (3A) (CANCER OR CARCINOMA))
L10	175 DUP REM L9 (265 DUPLICATES REMOVED)
L11	0 S 2',2'-DIFLOURORDEOXYCYTIDINE
L12	270678 S SYNERGIS### OR SYNERGY
L13	409 S L1 (P) L12
L14	265 S L1 (20A) L12
L15	108 DUP REM L14 (157 DUPLICATES REMOVED)

(FILE 'HOME' ENTERED AT 12:49:15 ON 30 NOV 1999)

FILE 'BIOSIS, MEDLINE, EMBASE, CAPLUS, CANCERLIT, TOXLINE, APIPAT,  
CROPU,  
DGENE, DPCI, EUROPATFULL, IFIPAT, INPADOC, JAPIO, PAPERCHEM2, PATDD,  
PATDPA, PATOSDE, PATOSEP, PATOSWO, PIRA, RAPRA, TULSA, TULSA2,  
USPATFULL'

ENTERED AT 12:49:45 ON 30 NOV 1999

L1 126 S (HER2 OR HER-2 OR NEU OR C-ERBB2 OR ERBB2 OR P185ERBB2) AND  
A  
L2 18 S L1 AND (CARDIO? OR HEART)  
L3 18 DUP REM L2 (0 DUPLICATES REMOVED)

Pull search  
notes from  
208,649

RC 261.A1.E87

L15 ANSWER 72 OF 108 MEDLINE  
AN 97308903 MEDLINE  
DN 97308903  
TI Combination therapy with gemcitabine in non-small cell lung cancer.  
AU Mosconi A M; Crin'o L; Tonato M  
CS Medical Oncology Division, Policlinico Hospital, Perugia, Italy.  
SO EUROPEAN JOURNAL OF CANCER, (1997 Jan) 33 Suppl 1 S14-7. Ref: 20  
Journal code: ARV. ISSN: 0959-8049.  
CY ENGLAND: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW, TUTORIAL)  
LA English  
FS Priority Journals; Cancer Journals  
EM 199708  
EW 19970802  
AB . . . rates of 20% and above. Because of its unique mechanism of  
action  
and its non-overlapping toxicity with other active agents,  
**gemcitabine** is an attractive candidate for trials in combination  
with other cytotoxic agents. In preclinical models, the cisplatin-  
**gemcitabine** combination suggested **synergy** between the  
two drugs. In phase I-II studies, response rates are as high as 54% when  
**gemcitabine** is combined with cisplatin, both in stage III and IV

10 ANSWER 103 OF 175 MEDLINE DUPLICATE 46  
AN 1998279251 MEDLINE  
DN 98279251  
TI Effective intrahepatic administration of **gemcitabine** after  
failure of doxorubicin in metastatic **breast cancer**  
[letter].  
AU Malayeri R; Wein W; Zielinski C  
SO EUROPEAN JOURNAL OF CANCER, (1997 Dec) 33 (14) 2435.  
Journal code: ARV. ISSN: 0959-8049.  
CY ENGLAND: United Kingdom  
DT Letter  
LA English  
FS Priority Journals; Cancer Journals  
EM 199808  
EW 19980803  
TI Effective intrahepatic administration of **gemcitabine** after  
failure of doxorubicin in metastatic **breast cancer**  
[lette